PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapy

BACKGROUND. Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, in addition to its antiangiogenic properties, sorafenib may beneficially reduce the extent of the immunosuppressive netwo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Kalathil, Suresh Gopi, Lugade, Amit Anand, Miller, Austin, Iyer, Renuka, Thanavala, Yasmin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4986927/
https://ncbi.nlm.nih.gov/pubmed/27540594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86182
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados